Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 18 June 2024, 19:00 HKT/SGT
Share:
    

Source: JBM (Healthcare) Limited
JBM Healthcare Announces FY2024 Annual Results
- Adjusted Profit* Surges 149.5% to HK$130.5 Million
- Flagship Brands Spearhead Growth with Effective Strategies
- Recommends Final Dividend of HK4.05 Cents Per Share

KEY HIGHLIGHTS

  • Year-on-year revenue increased by 24.6%, totalling HK$648.4 million
  • Adjusted profit attributable to equity shareholders* soared 149.5% to HK$130.5 million
  • The Board recommends a final dividend of HK4.05 cents per share
  • All three business segments exhibited robust growth momentum
  • Flagship proprietary brands Ho Chai Kung and Po Chai Pills led with impressive growth
  • Cross-border e-commerce continued to grow on various platforms

HONG KONG, June 18, 2024 - (ACN Newswire) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the "Group"), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the annual results of the Group for the year ended 31 March 2024 ("FY2024" or the "Reporting Period").

During the Reporting Period, the Group's branded healthcare business achieved a 24.6% increase in revenue, totaling HK$648.4 million. Gross profit for the same period rose by 64.5% to HK$338.1 million. Adjusted profit attributable to equity shareholders* surged by 149.5% to HK$130.5 million. This robust performance is primarily due to improved retail market sentiment and successful marketing strategies for key brands in the proprietary medicine category, notably Ho Chai Kung and Po Chai Pills.

The Board recommends a final dividend of HK4.05 cents per share. Including the interim dividend of HK3.45 cents per share already paid, the total dividend for FY2024 will be HK7.5 cents per share.

Effective Brand Management Fueled Robust Performance

In the branded medicines business, sales revenue achieved a significant growth of 53.3%, primarily attributable to the remarkable performance of Ho Chai Kung products. A widely recognised household name for over-the-counter painkillers and fever relief, Ho Chai Kung has experienced a significant boost in sales, which is attributed to its effective brand marketing strategy alongside effective sales channel management. The brand's launch of a new TV advertising campaign featuring celebrity Hins Cheung, has received a tremendous response from the audience. The creative campaign, "Trust Hin Gong, Use Ho Chai Kung", garnered substantial views and likes across various social media platforms, creating a trending topic in the city and significantly enhancing the brand's visibility in Hong Kong.

The proprietary Chinese medicines segment exhibited an overall 7.3% increase in revenue, fueled by the strong growth of Po Chai Pills and the sustained momentum of the Group's concentrated Chinese medicine granules business. During the Reporting Period, Po Chai Pills successfully launched a new TV advertisement named "Ivana's Po Chai Pills Digestive Tune" targeting a younger audience and reinforcing its leadership in Chinese gastrointestinal medicine. Renowned singer-song writer Ivana Wong lends her voice to a revamped version of the classic jingle, "Take Po Chai Pills for Rapid Relief", which resonates with viewers, invokes nostalgic memories and revitalises the brand.

Sustained Development in Cross-Border E-commerce  

The Group's cross-border e-commerce division continued its growth trajectory and remained a consistent contributor to the Group's profits. This was driven by strong demand for its proprietary brands, such as Ho Chai Kung and Po Chia Pills, as well as solid performances in the medical devices and beauty products segments. In the fourth quarter of 2023, the Group launched its Tmall Ho Chai Kung Overseas Flagship Store, intending to bolster the brand's image and recognition while expanding its consumer base in Mainland China.

Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, commented, "In FY2024, JBM Healthcare capitalised on promising growth opportunities amid the notable rebound of Hong Kong's retail sector, leveraging our strategic acumen and robust execution."

"As we forge ahead, we are poised to harness transformative trends in healthcare. We will prioritise operational excellence, productivity, and shareholder value while enhancing efficiency and actively expanding its sales platforms and geographic reach. By providing trusted, branded healthcare products, JBM Healthcare empowers consumers to better manage their health, aligning with its mission."

About JBM (Healthcare) Limited (Stock Code: 2161)

JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex, Mederma for Kids, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk 




Topic: Press release summary
Source: JBM (Healthcare) Limited

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



JBM (Healthcare) Limited
May 5, 2024 11:00 HKT/SGT
JBM Healthcare Issues Positive Profit Alert
Nov 22, 2023 19:50 HKT/SGT
JBM Healthcare Announces FY2024 Interim Results
June 15, 2023 23:40 HKT/SGT
JBM Healthcare Announces FY2023 Annual Results
Nov 25, 2022 23:25 HKT/SGT
JBM Healthcare Announces FY2023 Interim Results
June 15, 2022 19:56 HKT/SGT
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia
June 29, 2021 22:55 HKT/SGT
JBM Healthcare Announces FY2021 Annual Results
Feb 5, 2021 16:28 HKT/SGT
JBM (Healthcare) Limited Debuts on The Main Board of SEHK
Jan 25, 2021 17:20 HKT/SGT
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: